"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04390022","Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial","SAINT","Recruiting","No Results Available","Covid-19|Coronavirus Infection|SARS-CoV-2 Infection","Drug: Ivermectin|Drug: Placebo","Proportion of patients with a positive SARS-CoV-2 PCR|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel","Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health","All","18 Years to 59 Years   (Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SAINT","May 14, 2020","August 4, 2020","August 30, 2020","May 15, 2020",,"May 21, 2020","Clinica Universidad de Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT04390022"
2,"NCT04343092","Efficacy of Ivermectin as Add on Therapy in COVID19 Patients",,"Completed","No Results Available","COVID 19","Drug: Ivermectin (IVM)","Number of cured patients|Mean time to cure of the covid 19 patients","University of Baghdad","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO20040001","April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",,"June 5, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",,"https://ClinicalTrials.gov/show/NCT04343092"
3,"NCT04381884","Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19 Drug Treatment","Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.","Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2","Laboratorio Elea Phoenix S.A.|Universidad Nacional de Salta|Centro de Investigación Veterinaria Tandil CIVETAN|Hospital de Pediatría Prof Dr. Juan P. Garrahan|Universidad Nacional de Quilmes","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVM-AR-1","May 18, 2020","June 30, 2020","June 30, 2020","May 11, 2020",,"May 27, 2020","Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04381884"
4,"NCT02806414","Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.",,"Completed","No Results Available","Rosacea","Drug: Ivermectin","The change in biochemical markers of rosacea-specific inflammation, LL-37 and KLK5, after 12 weeks of topical ivermectin.|The correlation between the change in clinical rosacea assessments after 12 weeks of topical ivermectin application and the change in LL-37 and KLK5.","University of California, San Diego|Galderma","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCSD 160765","July 2016","July 2019","September 2019","June 20, 2016",,"September 26, 2019","UCSD Division of Dermatology, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02806414"
5,"NCT04407507","Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","SILVERBULLET","Not yet recruiting","No Results Available","COVID-19","Drug: Ivermectin|Drug: Placebo","Participants with a disease control status defined as no disease progression to severe.","Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","SARS-COV-IverMX-01","June 2020","August 2020","October 2020","May 29, 2020",,"May 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04407507"
6,"NCT04373824","Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study",,"Recruiting","No Results Available","COVID","Drug: Ivermectin","effect of Ivermectin on eradication of virus.","Max Healthcare Insititute Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHC-COVID-19- INV- ACT-BHR","April 25, 2020","July 25, 2020","July 25, 2020","May 4, 2020",,"May 4, 2020","Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04373824"
7,"NCT03459794","Ivermectin and Human Immunity",,"Completed","Has Results","Ivermectin","Drug: Ivermectin|Other: Placebo","The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded.|Number of Transcripts in PBMC With Statistically Significant Changes From Pre-treatment Levels.|Complete Blood Counts (CBC)","University of Georgia","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00005069","February 12, 2018","April 9, 2018","November 30, 2018","March 9, 2018","July 12, 2019","July 12, 2019","University of Georgia, Athens, Georgia, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03459794/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03459794"
8,"NCT02784743","Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali",,"Completed","No Results Available","Lymphatic Filariasis","Drug: ''albendazole'' and ''ivermectin''","vector infection and infectivity rates|Post MDA adverses events related to the drug albendazo and ivermectin|impact of albendazole ivermectin treatment on microfilaremia","Centre d'Appui à la lutte contre la Maladie|Malaria Research and Training Center, Bamako, Mali|World Health Organization","All","5 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","1139","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OMS/TDR ID# A00563","May 2001","December 2008","April 2015","May 27, 2016",,"May 27, 2016",,,"https://ClinicalTrials.gov/show/NCT02784743"
9,"NCT02963324","Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers","IVMPBPK","Completed","No Results Available","Malaria","Drug: Ivermectin","Maximum concentration (Cmax) of ivermectin in whole blood, plasma, and capillary blood|Time to maximum concentration (Tmax) of ivermectin in whole blood, plasma, and capillary blood|Area under the curve (AUC) of ivermectin in whole blood, plasma, and capillary blood|Occurence of adverse events|Laboratory changes|Changes in electrocardiogram (ECG)","University Hospital, Basel, Switzerland","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IVMPBPK","November 2016","December 2016","January 2017","November 15, 2016",,"February 1, 2017","University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT02963324"
10,"NCT03052998","Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy","OAETREAT","Completed","No Results Available","Ivermectin|Onchocerciasis|Epilepsy","Drug: Ivermectin","seizure freedom|>50 % reduction in seizure frequency","Robert Colebunders|Universiteit Antwerpen","All","5 Years and older   (Child, Adult, Older Adult)","Phase 4","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","B300201730821|ERC grant No.671055","October 1, 2017","December 31, 2017","August 1, 2018","February 14, 2017",,"January 7, 2019","Centre de Recherche en Maladies Tropicales de l'Ituri, Rethy, Ituri, Congo, The Democratic Republic of the",,"https://ClinicalTrials.gov/show/NCT03052998"
11,"NCT02036229","Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis",,"Unknown status","No Results Available","Demodicidosis|Rosacea","Drug: ivermectin cream 0.5%","A decrease in mite density in skin surface biopsy after treatment with topical ivermectin (≤5 mites/cm2 for skin lesions).|Clinical improvement|A comparable dermoscopic improvement in the demodicidosis features","Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","topical ivermectin, demodex","February 2014","December 2015","June 2016","January 14, 2014",,"January 13, 2015","RabinMC, Dermatology dept., Petah-Tiqva, Israel",,"https://ClinicalTrials.gov/show/NCT02036229"
12,"NCT03517462","Ocular Changes After Ivermectin - (DOLF IVM/Oncho)",,"Active, not recruiting","No Results Available","Onchocerciasis","Drug: Ivermectin 3Mg Tab","Number of participants with complete microfilaria clearance from the eye at 3 months|Number of participants with complete microfilaria clearance from the eye at 6 months|The change from baseline in the number of microfilaria detected in the skin at 3 months|The change from baseline in the number of microfilaria detected in the skin at 6 months|The change from baseline in the number of microfilaria detected in the eye at 3 months|The change from baseline in the number of microfilaria detected in the eye at 6 months|Number of participants with complete microfilaria clearance from the skin at 3 months|Number of participants with complete microfilaria clearance from the skin at 6 months","Washington University School of Medicine|Case Western Reserve University|University of Health and Allied Sciences","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","231","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","201804116","August 6, 2018","August 14, 2021","August 14, 2021","May 7, 2018",,"April 29, 2019","University of Health and Allied Sciences, Hohoe, Ghana",,"https://ClinicalTrials.gov/show/NCT03517462"
13,"NCT04332068","Ivermectin Safety in Small Children","ISSC","Not yet recruiting","No Results Available","Scabies","Drug: Oral ivermectin|Drug: Permethrin Cream|Other: Placebo tablet|Other: Placebo cream","Comparing the occurrence of adverse events between the intervention (ivermectin) and control (permethrin) groups|Population pharmacokinetic properties of ivermectin at escalating doses|Efficacy of oral ivermectin","University of Oxford|Chittagong Medical College|The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD)|Kenya Medical Research Institute|Manhiça Health Research Centre (CISM)","All","2 Months to 5 Years   (Child)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PAR20001","November 1, 2020","October 31, 2021","October 31, 2021","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04332068"
14,"NCT04392713","Efficacy of Ivermectin in COVID-19",,"Recruiting","No Results Available","COVID","Drug: Ivermectin 6 MG Oral Tablet (2 tablets)","Negative PCR|Need for mechanical ventilation","Combined Military Hospital, Pakistan","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVE-COV","April 15, 2020","July 2020","July 2020","May 19, 2020",,"May 19, 2020","Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT04392713"
15,"NCT02046200","Development of Ivermectin for Alcohol Use Disorders",,"Completed","Has Results","Alcohol Use Disorder","Drug: Ivermectin|Drug: Placebo|Drug: Alcohol","Heart Rate|Systolic Blood Pressure|Diastolic Blood Pressure|Subjective Effects of Alcohol Using the Alcohol Urge Questionnaire (AUQ)|Subjective Effects of Alcohol Using the Drug Effects Questionnaire (DEQ) - ""Feel"" Subscale|Subjective Effects of Alcohol Using the Drug Effects Questionnaire (DEQ) - ""Like"" Subscale|Subjective Effects of Alcohol Using the Drug Effects Questionnaire (DEQ) - ""More"" Subscale|Subjective Effects of Alcohol Using the Drug Effects Questionnaire (DEQ) - ""High"" Subscale|Subjective Effects of Alcohol Using the Biphasic Alcohol Effects Scale (BAES) - Stimulant Subscale|Subjective Effects of Alcohol Using the Biphasic Alcohol Effects Scale (BAES) - Sedative Subscale|Cue-induced Craving Using the Alcohol Urge Questionnaire (AUQ)|Adverse Effects|Ivermectin Pharmacokinetics: Peak Concentration (Cmax)|Ivermectin Pharmacokinetics: Time to Cmax (Tmax)|Ivermectin Pharmacokinetics: Area Under the Time-concentration Curve (AUC)|Ivermectin Pharmacokinetics: Half-life (T1/2)|Stress-induced Alcohol Craving","University of California, Los Angeles","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IVM|UL1TR000124","February 2014","March 2015","March 2015","January 27, 2014","April 13, 2017","August 8, 2018","UCLA Addictions Laboratory, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02046200"
16,"NCT03967054","Repeat Ivermectin Mass Drug Administrations for MALaria Control II","RIMDAMAL II","Recruiting","No Results Available","Malaria","Drug: Ivermectin|Drug: Placebo oral tablet","Malaria incidence|Adverse Events|Blood fed mosquito mortality|Entomological inoculation rate|Human antibody responses to an Anopheles salivary gland peptide|Plasmodium prevalence|Plasmodium parasitemia|Plasmodium multiplicity of infection|Plasmodium molecular force of infection","Brian Foy|Yale University|Institut de Recherche en Sciences de la Sante|Radboud University|PATH|Colorado State University","All","Child, Adult, Older Adult","Phase 3","4700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","18-1803H","July 13, 2019","December 2020","July 2023","May 30, 2019",,"August 28, 2019","Institut de Recherche en Sciences de la Sante, Diebougou, Sud-Ouest, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT03967054"
17,"NCT03432442","Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients","PKIDEN","Recruiting","No Results Available","Dengue Hemorrhagic Fever","Drug: Ivermectin","Pharmacokinetics of ivermectin in pediatric dengue patients|Pharmacodynamic effects of ivermectin on viral load in plasma of pediatric dengue patients|Pharmacodynamic effects of ivermectin on NS1 antigen in plasma of pediatric dengue patients|Viremia clearance|NS1 antigenemia clearance|Occurrences of adverse events|Occurrences of abnormal laboratory result","Mahidol University","All","1 Year to 15 Years   (Child)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VIR17003","September 4, 2018","July 31, 2019","July 31, 2019","February 14, 2018",,"January 17, 2019","Faculty of Tropical Medicine Siriraj Hospital, Bangkok Noi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT03432442"
18,"NCT04275999","Rosacea and Ivermectin",,"Not yet recruiting","No Results Available","Rosacea","Drug: ivermectin|Behavioral: digital interaction|Device: GPSkin","Adherence - MEMs Cap|Adherence - Drug Weight|Adherence - Drug Weight Change|Transepidermal water loss (TEWL) rates|Level of stratum corneum (SC) hydration|Level of stratum corneum (SC) hydration.","Wake Forest University Health Sciences|Galderma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00062694","July 2020","March 31, 2021","December 31, 2021","February 19, 2020",,"May 19, 2020","Wake Forest Health Sciences Dermatology, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04275999"
19,"NCT04403555","Ivermectin and Doxycycine in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine","The number of patients with resolved viral infection","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","tanta combo covid treatment","June 1, 2020","December 1, 2030","December 3, 2030","May 27, 2020",,"May 27, 2020","Sherief Abd-Elsalam, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04403555"
20,"NCT03605758","Treatment of Strongyloides Infection","TSSI","Recruiting","No Results Available","Strongyloides Stercoralis Infection|Strongyloidiasis","Drug: Ivermectin","Level of Strongyloides serology as measured by ELISA at 3-4 months post-treatment|Level of Strongyloides serology as measured by ELISA at 6-8 months post-treatment|Level of Strongyloides serology as measured by ELISA at 9-12 months post-treatment","Albert Einstein College of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-233","May 2012","December 2021","December 2021","July 30, 2018",,"July 30, 2018","Jacobi Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03605758"
21,"NCT03852303","Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy","OAETREATe","Completed","No Results Available","Epilepsy","Drug: ivermectin","seizure freedom","Universiteit Antwerpen|European Research Council","All","5 Years and older   (Child, Adult, Older Adult)","Phase 4","197","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B300201733349","October 1, 2017","March 31, 2019","July 1, 2019","February 25, 2019",,"September 26, 2019","Centre de Recherche en Maladies Tropicales de l'Ituri, Rethy, Ituri, Congo, The Democratic Republic of the",,"https://ClinicalTrials.gov/show/NCT03852303"
22,"NCT03690453","Effect of Ivermectin Metabolites on Mosquito Survival",,"Not yet recruiting","No Results Available","Healthy","Drug: Ivermectin","Area under the concentration-time curve for Ivermectin and its metabolites|Maximum concentration for Ivermectin and its metabolites|Time to maximum concentration for Ivermectin and its metabolites|Terminal elimination half-life for Ivermectin and its metabolites|Concentration associated with half maximum mosquito killing effect [LC50] for Ivermectin and its metabolites|Duration of mosquito survivorship|Compare Maximum Blood Concentrations (Cmax) for ivermectin components and metabolites measured between venous and capillary blood|Compare Area-Under-Curve (AUC) for ivermectin components and metabolites measured between venous and capillary blood|Compare mosquito (An. dirus) survival curves to day 14 between Direct Feeding Assay and Standard Membrane Feeding Assays|Compare mosquito (An. Minimus) survival curves to day 14 between Direct Feeding Assay and Standard Membrane Feeding Assays|The lethal concentration that kills 50% of mosquitoes (LC50) between two strains of An. dirus|Mosquito survival curves to day 14 between two strains of An. dirus.|The lethal concentration that kills 50% of mosquitoes (LC50) for each ivermectin component and synthesized metabolites|The inhibitory concentration that kills 50% of parasites (IC50) for each P. falciparum strain.|The structure of mosquito internal organs.","University of Oxford","All","18 Years to 60 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","MAL18006","February 4, 2019","July 1, 2019","September 1, 2019","October 1, 2018",,"January 28, 2019",,,"https://ClinicalTrials.gov/show/NCT03690453"
23,"NCT01570504","Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis","STRONGTREAT","Completed","No Results Available","Strongyloidiasis","Drug: Ivermectin","clearance of strongyloides infection|All-cause mortality during the 12 months of follow-up.|Patients with partial response to treatment at T 2|Patients with adverse reactions|Patients with increase in blood ALT over cutoff value|Patients with decrease in WBC count below cutoff value|Average difference in blood ALT and WBC count at day 17, compared with baseline|Average difference in blood eosinophil count at T2, compared with baseline","Centro per le Malattie Tropicali|European Commission","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","312","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTD1-2012|2011-002784-24","March 2013","June 8, 2018","June 8, 2018","April 4, 2012",,"June 14, 2018","Centro per le Malattie Tropicali, Ospedale Sacro Cuore, Negrar, Verona, Italy|Clinica di Malattie Infettive e Tropicali, Brescia, Italy|UFDID, Azienda Ospedaliero-universitaria Careggi, Florence, Italy|Unità di Malattie Infettive, Anna Meyer Children's Universisty Hospital, Florence, Italy|Unidad de Medicina, Hospital de Poniente-El Ejido, El Ejido, Almeria, Spain|FCRB, Hospital Clinic de Barcelona, Barcelona, Spain|Unitat Medicina Tropical i Salut Internacional Drassanes, Barcelona, Spain|Addenbrookes Hospital, Cambridge University Hospital, Cambridge, United Kingdom|UCLH, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01570504"
24,"NCT04374279","Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy","RECOVER","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab","Number of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV2003|IRB00249425","June 2020","June 2021","June 2021","May 5, 2020",,"May 5, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04374279"
25,"NCT00921219","Ivermectin Solution Bioequivalence Study - With Food (Repeat)",,"Completed","No Results Available","Healthy","Drug: ivermectin","Pharmacokinetic parameters, including AUC0-t, AUC0-inf and Cmax|Pharmacokinetic parameters, including t1/2, MRT=Mean residence time kel = Terminal Elimination Rate Constant, Tmax","Johnson & Johnson Consumer and Personal Products Worldwide","All","18 Years to 50 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SCO2005","September 2005","November 2005","November 2005","June 16, 2009",,"October 6, 2011",,,"https://ClinicalTrials.gov/show/NCT00921219"
26,"NCT00921154","Ivermectin Solution Bioequivalence Study - Fasted",,"Completed","No Results Available","Healthy","Drug: ivermectin","Pharmacokinetic parameters, including AUC0-t, AUC0-inf and Cmax|Pharmacokinetic parameters, including t1/2, Mean residence time, Terminal Elimination Rate Constant, and Tmax","Johnson & Johnson Consumer and Personal Products Worldwide","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SCO2704","March 2005","May 2005","September 2005","June 16, 2009",,"October 6, 2011","Shandon Clinic, Cork, Co. Cork, Ireland",,"https://ClinicalTrials.gov/show/NCT00921154"
27,"NCT00921674","Ivermectin Solution Bioequivalence Study - With Food",,"Completed","No Results Available","Healthy","Drug: ivermectin","Pharmacokinetic parameters, including AUC0-t, AUC0-inf, and Cmax|Pharmacokinetic parameters, including t1/2, Mean residence time (MRT), Terminal Elimination Rate Constant (kel) and Tmax","Johnson & Johnson Consumer and Personal Products Worldwide","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SCO2804","February 2005","April 2005","April 2005","June 16, 2009",,"October 6, 2011",,,"https://ClinicalTrials.gov/show/NCT00921674"
28,"NCT03717558","Bioavailability Pilot Study of Versus W0035 Versus Stromectol",,"Withdrawn","No Results Available","Healthy Volunteers","Drug: ivermectin T1|Drug: ivermectin T2|Drug: ivermectin T3","Concentration of ivermectin","Pierre Fabre Dermatology","Male","18 Years to 64 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","W00035 PU 1 02","April 30, 2018","April 30, 2018","April 30, 2018","October 24, 2018",,"October 24, 2018","Quotient Clinical, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03717558"
29,"NCT03257943","A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%",,"Completed","No Results Available","Lice; Head Lice","Drug: Ivermectin Lotion, 0.5%|Drug: SKLICE (ivermectin) Lotion, 0.5%|Drug: Vehicle of the Test product","Demonstration of Bioequivalence in proportion of index subjects who are lice free","Taro Pharmaceuticals USA","All","18 Years and older   (Adult, Older Adult)","Phase 1","413","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IVRL 1604","March 20, 2017","June 27, 2017","August 18, 2017","August 22, 2017",,"May 18, 2018","Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT03257943"
30,"NCT01068158","A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","LICE OUT","Completed","Has Results","Head Lice","Drug: 0.5% Ivermectin Cream|Drug: Placebo control","Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Summary of the Reported Skin/Scalp Irritation Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)","Topaz Pharmaceuticals Inc","All","5 Months and older   (Child, Adult, Older Adult)","Phase 3","371","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TOP012","March 2010","June 2010","July 2010","February 12, 2010","April 4, 2012","April 6, 2012","Arkansas Pediatric Clinic, Little Rock, Arkansas, United States|Lice Cleanique, LLC, Delray Beach, Florida, United States|Hill Top Research, St Petersburg, Florida, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Haywood Pediatric and Adolescent Medicine Group, PA, Clyde, North Carolina, United States|LSRN, Nashville, Tennessee, United States|Northeast Houston Pediatric Clinic, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01068158"
31,"NCT04106726","Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea",,"Active, not recruiting","No Results Available","Facial Rosacea","Drug: Soolantra® Ivermectin cream 1%|Drug: Ivermectin cream 1%|Drug: Placebo for Ivermectin cream 1%","Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.|Exploratory Endpoint: The proportion of subjects with a clinical response (IGA) of ""success"" at week 12.","Zydus Worldwide DMCC|Catawba Research, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","525","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IVRC 1907","October 17, 2019","July 31, 2020","August 31, 2020","September 27, 2019",,"March 4, 2020","Zydus Worldwide DMCC, Brandon, Florida, United States|Zydus Worldwide DMCC, Fort Lauderdale, Florida, United States|Zydus Worldwide DMCC, Miami, Florida, United States|Zydus Worldwide DMCC, Miramar, Florida, United States|Zydus Worldwide DMCC, Tampa, Florida, United States|Zydus Worldwide DMCC, Saginaw, Michigan, United States|Zydus Worldwide DMCC, High Point, North Carolina, United States|Zydus Worldwide DMCC, Sugarloaf, Pennsylvania, United States|Zydus Worldwide DMCC, Upper Saint Clair, Pennsylvania, United States|Zydus Worldwide DMCC, El Paso, Texas, United States|Zydus Worldwide DMCC, El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04106726"
32,"NCT03876262","Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis",,"Not yet recruiting","No Results Available","Onchocerciasis","Drug: Moxidectin|Drug: Ivermectin","Proportion of moxidectin annual and biannual recipients with sustained microfilarial response at month 12|Incidence and severity of adverse events|Proportion of participants in all dose groups with sustained microfilariae response|Sustained ocular microfilariae response in all dose groups|Skin microfilarial density in all dose groups|Proportion of participants in all dose groups with 0 Onchocerca volvulus microfilariae/mg skin and 0 live microfilariae in the anterior chambers of the eyes each timepoint","Medicines Development for Global Health","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MDGH-MOX-3001","August 2020","October 2023","October 2023","March 15, 2019",,"February 28, 2020","Centre de Recherche pour les Maladies Tropicales Negligees, Rethy, Ituri, Congo, The Democratic Republic of the",,"https://ClinicalTrials.gov/show/NCT03876262"
33,"NCT00790998","Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection",,"Completed","No Results Available","Onchocerciasis","Drug: Moxidectin|Drug: Ivermectin","skin microfilaria density (mf/mg)|skin microfilaria reduction from baseline|proportion of subjects with undetectable levels of skin microfilaria|percent reduction in microfilaria levels in the anterior chamber of the eye","Medicines Development for Global Health|World Health Organization","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1497","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3110A1-3000|B1751006 - ONCBL60801","April 2009","February 2012","May 2012","November 14, 2008",,"January 31, 2018","Centre de Recherche Clinique de Butembo - Université Catholique du Graben, Butembo, Congo, The Democratic Republic of the|Centre de Recherche en Maladies Tropicales de l'Ituri, Rethy, Congo, The Democratic Republic of the|Onchocerciasis Chemotherapy Research Center, Hohoe, Ghana|Liberian Institute for Biomedical Research Clinical Research Center, Bolahun, Lofa County, Liberia",,"https://ClinicalTrials.gov/show/NCT00790998"
34,"NCT02509481","Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study","RIMDAMAL","Completed","Has Results","Malaria|Lymphatic Filariasis","Drug: Ivermectin|Drug: Albendazole","Incidence of Clinical Malaria Episodes|Adverse Events|Entomological Indicator of Parasite Transmission|Molecular Force of P. Falciparum Infection|Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH)|Entomological Inoculation Rate","Colorado State University|Institut de Recherche en Sciences de la Sante, Burkina Faso|Centre Muraz|Ministère de la Santé du Burkina Faso","All","Child, Adult, Older Adult","Phase 2|Phase 3","2712","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","5375011|OPP1116536","June 2015","November 2015","December 2015","July 28, 2015","January 4, 2019","January 4, 2019","Colorado State University, Fort Collins, Colorado, United States|Institut de Recherche en Sciences de la Santé, Bobo Dioulasso, Houet, Burkina Faso","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02509481/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02509481"
35,"NCT02841215","Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies","GALECRUSTED","Unknown status","No Results Available","Gale|Severe Forms of Scabies|Oral Parasitic Drug|Ivermectin","Drug: Ivermectin 200 µg/kg|Drug: Ivermectin 400 µg/kg","Rate of a successful treatment defined by : -Two negative parasitologic or two dermoscopic exams|Rate of a successful treatment defined by : - A clinical response : disappearance of clinical active lesions|Rate of adverse effects","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P140939","March 2017","March 2019","March 2019","July 22, 2016",,"December 8, 2016","Henri Mondor Hospital, Creteil, France",,"https://ClinicalTrials.gov/show/NCT02841215"
36,"NCT04360356","Ivermectin and Nitazoxanide Combination Therapy for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care","Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio ""INR"" for prothrombin time|Number of patients with normalized complete blood count ""CBC""|The Mortality rate among treated patients","Tanta University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IVR/NTZ","May 2020","October 2020","December 2020","April 24, 2020",,"April 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04360356"
37,"NCT00765024","Ivermectin Versus Albendazole for Chronic Strongyloidiasis",,"Completed","No Results Available","Chronic Strongyloidiasis","Drug: Ivermectin|Drug: ivermectin|Drug: Albendazole","cure rate|safety","Mahidol University|Atlantic Laboratory Ltd","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TM001-2008","July 2008","April 2010","April 2010","October 2, 2008",,"September 7, 2017","Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00765024"
38,"NCT00857948","Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation",,"Completed","Has Results","Pediculus Humanus Capitis (Head Lice)","Drug: ivermectin treatment conditioner|Drug: Placebo, vehicle control","Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Percentage of Index Participants Who Were Lice-Free at Different Time Points Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Level of Live Lice Infestation at Different Time Points Post-Treatment With Either Ivermectin or Placebo (Vehicle Control)|Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control).","Topaz Pharmaceuticals Inc","All","6 Months and older   (Child, Adult, Older Adult)","Phase 2","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TOP003","March 2009","April 2009","April 2009","March 9, 2009","March 30, 2012","March 30, 2012","Global Health Associates of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00857948"
39,"NCT02511353","Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study","IVERMAL","Completed","No Results Available","Malaria","Drug: ivermectin|Drug: placebo|Drug: dihydroartemisinin-piperaquine","Mosquito survival|Number of patients with malaria clinical and parasitological treatment response|Area under the plasma concentration versus time curve (AUC) of ivermectin|Area under the plasma concentration versus time curve (AUC) of piperaquine|Peak plasma Concentration (Cmax) of ivermectin|Peak plasma Concentration (Cmax) of piperaquine|Tolerability as assessed by adverse events reported in a general toxicity questionnaire|CNS adverse events|Serious adverse events|Haemoglobin concentrations|QTc interval|Mydriasis quantitated by pupillometry","Liverpool School of Tropical Medicine|Kenya Medical Research Institute|Centers for Disease Control and Prevention","All","18 Years to 50 Years   (Adult)","Phase 2","141","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14.002|2775|6720","July 2015","July 2016","July 2016","July 30, 2015",,"August 23, 2018","Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT02511353"
40,"NCT01066585","A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation","LICE OUT","Completed","Has Results","Head Lice","Drug: Ivermectin Cream|Drug: vehicle control","Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)|Summary of the Reported Skin/Scalp Irritation Before Treatment and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)","Topaz Pharmaceuticals Inc","All","6 Months and older   (Child, Adult, Older Adult)","Phase 3","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TOP011","March 2010","June 2010","July 2010","February 10, 2010","April 4, 2012","April 6, 2012","Cactus Kids Pediatrics, Yuma, Arizona, United States|Universal Biopharma Research, Inc, Dinuba, California, United States|Lice Source Services, Inc., Plantation, Florida, United States|LSRN, West Palm, Florida, United States|Spence Medical Research, Picayune, Mississippi, United States|Hill Top Research, Miamiville, Ohio, United States|McKenzie Medical Center, McKenzie, Tennessee, United States|Virginia Clinical Research, Inc., Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01066585"
41,"NCT03301649","Clinical Endpoint Study of Ivermectin 0.5% Lotion",,"Completed","Has Results","Head Lice","Drug: Generic Ivermectin Lotion 0.5%|Drug: Sklice® (Ivermectin) Lotion 0.5%|Drug: Vehicle Lotion","Percentage of Index Participants Who Were Considered a Treatment Success: PP Population|Percentage of Index Participants Who Were Considered a Treatment Success: mITT Population|Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: PP Population|Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: mITT Population","Actavis Inc.|Teva Pharmaceuticals USA","All","6 Months and older   (Child, Adult, Older Adult)","Phase 3","905","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","71691702","October 7, 2017","March 12, 2018","March 12, 2018","October 4, 2017","December 20, 2019","December 20, 2019","Site 1, Miami, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03301649/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03301649/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03301649"
42,"NCT03553615","Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis",,"Withdrawn","No Results Available","Atopic Dermatitis","Drug: Ivermectin Pill","DLQI|EASI|TSS|IGA|VAS for Pruritis","Stanford University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-46486","December 2018","December 2019","December 2020","June 12, 2018",,"April 10, 2019","Stanford Hospital and Clinics, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03553615"
43,"NCT02045069","Efficacy and Safety of Ivermectin Against Dengue Infection",,"Unknown status","No Results Available","Dengue Fever","Drug: 2 days Ivermectin|Drug: 3 days Ivermectin|Drug: Placebo","Time to resolution of viremia|Time to clearance of NS1 antigen|Time of subsidence of fever","Mahidol University|Ministry of Health, Thailand","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ESIDEN","February 2014","February 2016","March 2016","January 24, 2014",,"November 2, 2015","Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02045069"
44,"NCT00819520","Ivermectin in the Treatment of Head Lice",,"Completed","No Results Available","Lice Infestations","Drug: ivermectin|Drug: malathion","Absence or presence of live head lice|Absence or presence of live head lice at alternative Study Days.|Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.","Johnson & Johnson Consumer and Personal Products Worldwide","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","812","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","075-00","February 2004","September 2004","October 2004","January 9, 2009",,"August 22, 2011","Hopital Avicenne, Bobigny, Paris, France|Shandon Clinic, Cork, Co. Cork, Ireland|Chaim Sheba Medical Centre, Tel Hashomer, Israel|Synexus Clinical Research Centre, Reading, Berks, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00819520"
45,"NCT02407782","Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children","SCRATCH","Unknown status","No Results Available","Scabies","Drug: Ivermectin|Drug: Permethrin","Assessment of skin lesions and healing at day 28|Assessment of skin lesions and healing at day 56|Assessment of skin lesions and healing at day 28 and 56 in children|Number of unaffected members in clusters treated by permethrin versus ivermectin at D0, D28 and D56.|Evaluation of delta wing jet sign(s) and mite egs|Incidence of serious adverse events|adherence of patients","University Hospital, Bordeaux","All","up to 16 Years   (Child)","Phase 3","502","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CHUBX 2011/16","January 2016","September 2017","September 2017","April 3, 2015",,"June 6, 2016","CHU de Bordeaux Hôpital Pellegrin, Bordeaux, Aquitaine, France|CHG de Chalon sur Saône, Chalon sur Saône, Bourgogne, France|CHU de Dijon, Dijon, Bourgogne, France|CHU de Rennes, Rennes, Bretagne, France|CHRU de Tours, Tours, Centre-Val de Loire, France|CH d'Argenteuil, Argenteuil, Ile de France, France|CHU de Créteil - Hôpital Henry Mondor, Créteil, Ile de France, France|AP-HP - Hôpital Robert Debré, Paris, Ile de France, France|CHU de Montpellier, Montpellier, Languedoc-Roussillon, France|CHU de la Réunion, Saint-Pierre, Martinique, France|CHU d'Angers, Angers, Pays de La Loire, France|CH du Mans, Le Mans, Pays de la Loire, France|CHU de Nantes, Nantes, Pays de la Loire, France|CHI de Fréjus, Fréjus, Provence-Alpes-Côte d'Azur, France|CHU de Nice, Nice, Provence-Alpes-Côte-d'Azur, France|CHU de Lyon, Bron, Rhône-Alpes, France",,"https://ClinicalTrials.gov/show/NCT02407782"
46,"NCT00994422","Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects",,"Completed","Has Results","Head Lice","Drug: Ivermectin cream|Drug: vehicle control","Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control)|Number of Participants Reporting Adverse Events Post-Treatment With Either Ivermectin or Placebo (Vehicle Control)|Summary of the Reported Skin/Scalp Irritations Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)","Topaz Pharmaceuticals Inc","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","264","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TOP010","October 2009","December 2009","December 2009","October 14, 2009","April 4, 2012","April 6, 2012","Cactus Kids Pediatrics, Yuma, Arizona, United States|Impact Clinical Trials, Los Angeles, California, United States|Lice Cleanique, LLC, Delray Beach, Florida, United States|Hill-Top Research Corp, St Petersburg, Florida, United States|LSRN, West Palm Beach, Florida, United States|Minnesota Clinical Study Center, Fridley, Minnesota, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Haywood Pediatric Adolescent Medicine Group, PA, Clyde, North Carolina, United States|Hill Top Research Corp., Miamiville, Ohio, United States|LSRN, Nashville, Tennessee, United States|Northeast Houston Pediatric Clinic, Houston, Texas, United States|Virgina Clinical Research, Inc., Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00994422"
47,"NCT04311671","Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas",,"Not yet recruiting","No Results Available","Onchocerciasis","Drug: Moxidectin|Drug: Ivermectin","Incidence and severity of treatment emergent adverse events","Medicines Development for Global Health","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","12500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MDGH-MOX-3002","October 9, 2020","August 6, 2021","August 6, 2021","March 17, 2020",,"May 14, 2020","Centre de Recherche pour les Maladies Tropicales Negligees, Rethy, Ituri, Congo, The Democratic Republic of the",,"https://ClinicalTrials.gov/show/NCT04311671"
48,"NCT02236403","Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%",,"Completed","No Results Available","Chronic Blepharitis","Drug: Ivermectin 0.1% Metronidazole 1%","Erradication of Demodex mites|Change in lid margin rednes and bulbar conjunctival hyperemia categorized from 0 (none) to 3 (severe) according to the next score","Universidad Nacional de Colombia","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","demodex0.1","October 2014","January 2015","January 2015","September 10, 2014",,"February 19, 2015","Hospital de Engativa, Bogotá, Colombia",,"https://ClinicalTrials.gov/show/NCT02236403"
49,"NCT01593722","Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis",,"Completed","Has Results","Loiasis","Drug: Diethylcarbamazine|Drug: Ivermectin","The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment.|The Frequency of Adverse Events|Eosinophil Activation|Proportion of Subjects Who Clear Microfilaremia","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","20 Years to 60 Years   (Adult)","Phase 4","155","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","999912117|12-I-N117","April 2012","August 2013","January 2014","May 8, 2012","November 9, 2016","November 9, 2016","Filariasis and other Tropical Diseases Research Center, Yaounde, Cameroon",,"https://ClinicalTrials.gov/show/NCT01593722"
50,"NCT04351347","The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Nitazoxanide|Drug: Ivermectin","Number of patients with virological cure","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ivermecin covid","April 17, 2020","December 1, 2030","December 1, 2030","April 17, 2020",,"April 17, 2020","Tanta University, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04351347"
51,"NCT03286101","Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos",,"Completed","No Results Available","Pediculosis Capitis","Drug: 0.5% Ivermectin lotion|Drug: Vehicle","Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment.","United Laboratories","All","3 Years and older   (Child, Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD2017-01","September 14, 2017","October 12, 2017","November 9, 2017","September 18, 2017",,"March 7, 2018","Clinical Trial Management and Testing Associates, Inc., Muntinlupa, Philippines",,"https://ClinicalTrials.gov/show/NCT03286101"
52,"NCT00988533","A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age",,"Completed","Has Results","Head Lice","Drug: 0.5% Ivermectin Cream","Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points|Summary of Pharmacokinetic Parameters Following Ivermectin Application.|Summary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application.|Summary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application.|Number of Participants Reporting Adverse Events Following Ivermectin Treatment|Percentage of Participants Who Were Lice-Free by Visit Post-treatment With Ivermectin.|Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 8 and Day 15 Post-treatment With Ivermectin.|Liver Function Test Results at Before (Day 1) and Following Ivermectin Application on Days 2, 8, and 15 Post-application|Liver Function Test Results at Before (Baseline) and Following Ivermectin Application on Days 2, 8, and 15 Post-application","Topaz Pharmaceuticals Inc","All","6 Months to 3 Years   (Child)","Phase 1","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOP008","September 2009","November 2009","November 2009","October 2, 2009","April 25, 2012","April 25, 2012","Children's Investigational Research Program, Bentonville, Arkansas, United States|Universal BioPharma Research, Inc, Dinuba, California, United States|Impact Clinical Trials, Los Angeles, California, United States|Lice Source Solutions Inc, Plantation, Florida, United States|Spence Medical Research L.L.C, Picayune, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT00988533"
53,"NCT03527732","Efficacy and Safety of IVM/ALB Co-administration",,"Recruiting","No Results Available","Trichuriasis","Drug: Albendazole|Drug: Albendazole and Ivermectin","Cure rate against T. trichiura|Egg-reduction rate (ERR) against T. trichiura|Cure rates (CRs) against concomitant soil-transmitted helminth infections.|Egg-reduction rates (ERRs) against concomitant soil-transmitted helminth infections.|Adverse events|Infection status assessed by PCR|Maximum concentration (Cmax) of ivermectin, albendazole and albendazole metabolites|Time to reach Cmax (tmax) of ivermectin, albendazole and albendazole metabolites|Area under the curve (AUC) for ivermectin, albendazole and albendazole metabolites","Jennifer Keiser|Centre Suisse de Recherches Scientifiques en Cote d'Ivoire|Lao Tropical and Public Health Institute|Public Health Laboratory of Pemba, Tanzania|Swiss Tropical & Public Health Institute","All","6 Years to 60 Years   (Child, Adult)","Phase 2|Phase 3","1960","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1","April 15, 2018","December 2020","December 2020","May 17, 2018",,"September 26, 2019","Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS), Abidjan, Côte D'Ivoire|Lao Tropical and Public Health Institute, Sisattanak, Lao People's Democratic Republic|Public Health Laboratory Ivo de Carneri, P.O. Box 122, Chake Chake, Pemba, Tanzania",,"https://ClinicalTrials.gov/show/NCT03527732"
54,"NCT04392427","New Antiviral Drugs for Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID|Drug Effect","Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :","negative test result for COVID-19","Mansoura University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20.05.69","May 2020","May 2022","May 2022","May 18, 2020",,"May 18, 2020","Mansoura University, Mansoura, Select A State Or Province, Egypt",,"https://ClinicalTrials.gov/show/NCT04392427"
55,"NCT04391127","Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo","Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization","Centenario Hospital Miguel Hidalgo","All","16 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2020-A-09","May 4, 2020","August 30, 2020","September 30, 2020","May 18, 2020",,"May 27, 2020","Jose Manuel Arreola Guerra, Aguascalientes, Mexico",,"https://ClinicalTrials.gov/show/NCT04391127"
56,"NCT01493947","CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study","ATTRACT","Completed","Has Results","Papulopustular Rosacea","Drug: Ivermectin 1% cream|Drug: Metronidazole 0.75% cream","Percent Change in Inflammatory Lesions From Baseline to Week 16","Galderma R&D","All","18 Years and older   (Adult, Older Adult)","Phase 3","962","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","RD.03.SPR.40173","April 2012","December 2013","December 2013","December 16, 2011","October 28, 2015","October 28, 2015","Galderma Investigational Site, Pleven, Bulgaria|Galderma Investigational Site, Plovdiv, Bulgaria|Galderma Investigational Site, Sofia, Bulgaria|Galderma Investigational Site, Chomutov, Czech Republic|Galderma Investigational Site, Hradec Kralove, Czech Republic|Galderma Invetigational site, Olomouc, Czech Republic|Galderma Investigational Site, Pardubice, Czech Republic|Galderma Investigational Site, Praha 1, Czech Republic|Galderma Investigational Site, Slany, Czech Republic|Galderma Investigational Site, Bordeaux, France|Galderma Investigational Site, Brest, France|Galderma Investigational Site, Cannes, France|Galderma Investigational Site, Nice, France|Galderma Investigational Site, Saint Etienne, France|Galderma Investigational Site, Augsburg, Germany|Galderma Investigational Site, Berlin, Germany|Galderma Investigational Site, Bonn, Germany|Galderma Investigational Site, Darmstadt, Germany|Galderma Investigational Site, Dresden, Germany|Galderma Investigational Site, Hamburg, Germany|Galderma Investigational Site, Langenau, Germany|Galderma Investigational Site, Mahlow, Germany|Galderma Investigational Site, Mainz, Germany|Galderma Investigational Site, Munich, Germany|Galderma Investigational Site, Munster, Germany|Galderma Investigational Site, Tubingen, Germany|Galderma Investigational Site, Wuppertal, Germany|Galderma Investigational Site, Budapest, Hungary|Galderma Investigational Site, Budapest, Hungary|Galderma Investigational Site, Budapest, Hungary|Galderma Investigational Site, Budapest, Hungary|Galderma Investigational Site, Debrecen, Hungary|Galderma Investigational Site, Miskolc, Hungary|Galderma Investigational Site, Pecel, Hungary|Galderma Investigational Site, Szeged, Hungary|Galderma Investigational Site, Szekszard, Hungary|Galderma Investigational Site, Szolnok, Hungary|Galderma Investigational Site, Bialystok, Poland|Galderma Investigational Site, Gdansk, Poland|Galderma Investigational Site, Krakow, Poland|Galderma Investigational Site, Warszawa, Poland|Galderma Investigational Site, Wroclaw, Poland|Galderma Investigational Site, Brasov, Romania|Galderma Investigational Site, Bucharest, Romania|Galderma Investigational Site, Craiova, Romania|Galderma Investigational Site, Timisoara, Romania|Galderma Investigational Site, Tirgu Mures, Romania|Galderma Investigational Site, Chelyabinsk, Russian Federation|Galderma Investigational Site, Lipetsk, Russian Federation|Galderma Investigational Site, Moscow, Russian Federation|Galderma Investigational Site, Nizhny Novgorod, Russian Federation|Galderma Investigational Site, Dnipropetrovsk, Ukraine|Galderma Investigational Site, Donetsk, Ukraine|Galderma Investigational Site, Kiev, Ukraine|Galderma Investigational Site, Lviv, Ukraine|Galderma Investigational Site, Uzhgorod, Ukraine|Galderma Investigational Site, Berkshire, United Kingdom|Galderma Investigational Site, Bexhill, United Kingdom|Galderma Investigational Site, London, United Kingdom|Galderma Investigational Site, Nuneaton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01493947"
57,"NCT01975441","Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa",,"Completed","No Results Available","Lymphatic Filariasis","Drug: Diethylcarbamazine|Drug: Albendazole|Drug: Ivermectin","Percentage of subjects with total clearance of in Wuchereria bancrofti (Wb) microfilaria (mf)|Percentage of subjects with total clearance of Mf at 24 months.|Percent reduction in W. bancrofti antigen levels compared to baseline measured at 24 and 36 months|Percent of subjects who become circulating antigen negative at 24 months and 36 months after the beginning of the study","University Hospitals Cleveland Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CWRU 3 vs 2 LF ELIM PNG","May 2014","December 2017","June 2018","November 3, 2013",,"October 9, 2018","Papua New Guinean Institute for Medical Research, Maprik, East Sepik, Papua New Guinea",,"https://ClinicalTrials.gov/show/NCT01975441"
58,"NCT04407130","Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.",,"Not yet recruiting","No Results Available","COVID-19 Patients","Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo","Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >88% despite oxygenation|Number of days on oxygen support|Chest X-ray improvement|Duration of hospitalization|All causes of mortality","International Centre for Diarrhoeal Disease Research, Bangladesh","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PR-20039","June 2020","July 2020","July 2020","May 29, 2020",,"May 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04407130"
59,"NCT04405843","Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ivermectin Oral Product|Drug: Placebo","Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention","Centro de Estudios en Infectogía Pediatrica","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ScDi823","June 2020","October 2020","November 1, 2020","May 28, 2020",,"May 28, 2020",,,"https://ClinicalTrials.gov/show/NCT04405843"
60,"NCT02775617","Azithromycin - Ivermectin Mass Drug Administration for Skin Disease","AIM-Skin","Completed","Has Results","Scabies|Yaws|Impetigo","Drug: Ivermectin|Drug: Azithromycin|Drug: Permethrin","Impetigo Prevalence at 12 Months|Group A Streptococcus at 12 Months|Antimicrobial Resistance in Culture Isolates","London School of Hygiene and Tropical Medicine|Atoifi Adventist Hospital, Solomon Islands|Kirby Institute|Murdoch Childrens Research Institute","All","Child, Adult, Older Adult","Phase 4","1291","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","35148A","July 2016","August 2017","February 5, 2018","May 17, 2016","September 13, 2019","September 17, 2019","Atoifi Adventist Hospital, Atoifi, Malaita, Solomon Islands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02775617/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02775617"
61,"NCT02845713","Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)",,"Completed","No Results Available","Wuchereria Bancrofti Infection","Drug: Ivermectin, Diethylcarbamazine Albendazole (IDA)","Drug Levels|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (aggregate)|Impact of treatment on Hematuria and Proteinuria|Number worm nests|Impact of treatment on Liver Function +|Impact of treatment on Hemoglobin Levels|Impact of treatment on White Blood Cells","University Hospitals Cleveland Medical Center|Washington University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","66","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","03-16-09","April 17, 2016","June 2016","June 4, 2016","July 27, 2016",,"April 26, 2019","Agboville District Hospital, Agbobille, Côte D'Ivoire",,"https://ClinicalTrials.gov/show/NCT02845713"
62,"NCT02840461","Clinical Endpoint Study of Ivermectin 1% Cream",,"Completed","Has Results","Moderate to Severe Papulopustular Rosacea","Drug: Ivermectin Cream, 1%|Drug: Placebo/Vehicle cream","Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.|The Percentage of Patients With a Clinical Response of ""Success"".","Actavis Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","630","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","71591701","June 2016","November 2016","December 2016","July 21, 2016","June 2, 2020","June 2, 2020","Investigator site 1, Arlington Heights, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02840461"
63,"NCT01213576","Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi","FED","Terminated","Has Results","Lymphatic Filariasis","Drug: Albendazole 400mg and ivermectin 200mcg/kg|Drug: Albendazole and ivermectin|Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually","Number of Participants Achieving Microfilarial Clearance|Number of Participants With Microfilarial Clearance at 24 Months of Follow up","London School of Hygiene and Tropical Medicine|Emory University","All","18 Years to 55 Years   (Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FED-311207","January 2009","February 2012","February 2012","October 4, 2010","February 27, 2015","February 27, 2015","Karonga Prevention Study, Karonga, Malawi",,"https://ClinicalTrials.gov/show/NCT01213576"
64,"NCT04399746","Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19","IvAzCol","Recruiting","No Results Available","COVID","Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol","Viral clearance|Symptoms duration|SpO2|SpO2/FiO2","Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IvAzCol","March 15, 2020","May 20, 2020","June 10, 2020","May 22, 2020",,"May 22, 2020","Outpatient treatment, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04399746"
65,"NCT03570814","Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin",,"Not yet recruiting","No Results Available","Trachoma|Lymphatic Filariases","Drug: Administration of Albendazole on Day 1|Drug: Administration of Ivermectin on Day 1|Drug: Administration of Azithromycin on Day 1|Drug: Administration of Azithromycin on Day 15","Self Reported Adverse Event|Cost of Administration Drug Separately compared to Cost of Co-Administration of Drugs|Community perceptions","London School of Hygiene and Tropical Medicine|Armauer Hansen Research Institute, Ethiopia|Federal Minstry of Health of Ethiopia","All","Child, Adult, Older Adult","Phase 4","16000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11985","March 2020","September 2020","December 2021","June 27, 2018",,"February 20, 2020",,,"https://ClinicalTrials.gov/show/NCT03570814"
66,"NCT01603251","Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission","ACTIVE","Completed","No Results Available","Malaria","Drug: Artemether-lumefantrine combination|Drug: Artemether-lumefantrine combination + single dose Ivermectin|Drug: Artemether-lumefantrine combination + repeated dose Ivermectin","Safety|Mosquitocidal activity","London School of Hygiene and Tropical Medicine|Radboud University|Centre national de recherche et de formation sur le paludisme","All","15 Years to 25 Years   (Child, Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACTIVE","January 2013","April 2013","April 2013","May 22, 2012",,"April 18, 2013","Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT01603251"
67,"NCT03578679","Treatment of Pediculosis (Head Lice) in Senegal","IVERAZITH","Completed","No Results Available","Pediculoses","Drug: Ivermectin Oral Product","Parasiticidal efficacy: disappearance of head lice (zero lice) on day 7","Institut de Recherche pour le Developpement","Female","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SEN17/16","July 11, 2018","January 31, 2019","February 24, 2019","July 6, 2018",,"February 27, 2019","Institut de Recherche pour le Developpement, Dakar, Senegal",,"https://ClinicalTrials.gov/show/NCT03578679"
68,"NCT03337490","A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice",,"Completed","No Results Available","Head Lice","Drug: Ivermectin 0.5% Topical Application Lotion|Drug: Ivermectin 0.5% Topical Application Lotion [SKLICE]|Drug: Placebo 0% Lotion","The proportion of index subjects who are lice free at Day 15|The number of all index subjects who are lice-free at Day 2|The percentage of all index subjects who are lice-free at Day 2","bioRASI, LLC","All","6 Months to 18 Years   (Child, Adult)","Phase 3","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MAP-7189","October 2, 2017","December 4, 2017","December 18, 2017","November 9, 2017",,"January 24, 2018","Site 105, Dinuba, California, United States|Site 104, Miami, Florida, United States|Site 101, Plantation, Florida, United States|Site 102, West Palm Beach, Florida, United States|Site 106, Nashville, Tennessee, United States|Site 103, Richland, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03337490"
69,"NCT03036059","Twice Yearly Treatment for the Control of LF",,"Completed","No Results Available","Lymphatic Filariasis|Helminth Infection","Drug: 400 μg/kg Ivermectin + 400 mg Albendazole","Change from baseline prevalence of Lymphatic Filariasis at 24 months|Longitudinal assessment of transmission dynamics of Lymphatic Filariasis for modelling the impact of treatment|Evaluation of community acceptability of twice-yearly treatment, through questionnaires and focus group discussions|Feasibility of scale-up of twice-yearly treatment, through questionnaires and focus group discussions","Noguchi Memorial Institute for Medical Research|Ghana Health Services","All","5 Years and older   (Child, Adult, Older Adult)","Phase 4","1462","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMA 2015 CDF - 976","May 19, 2017","December 8, 2019","December 8, 2019","January 30, 2017",,"February 26, 2020","Noguchi Memorial Institute for Medical Research, Legon-Accra, Ghana",,"https://ClinicalTrials.gov/show/NCT03036059"
70,"NCT04049851","Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients","EOLoa","Not yet recruiting","No Results Available","Onchocerciasis, Ocular|Loiasis","Drug: Moxidectin 2 MG Oral Tablet|Drug: Ivermectin 3Mg Tab|Drug: Placebo oral tablet","Incidence of severe adverse events post Moxidectin 2 mg|Incidence of adverse events with Moxidectin 2 mg|Proportion of reduction of the microfilarial densities of Loa loa : short term efficacy|Proportion of reduction of the microfilarial densities of Loa loa : long term efficacy|Percentage of individuals without microfilaria post Moxidectin 2 mg","Institut National de la Santé Et de la Recherche Médicale, France","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C18-57","January 15, 2020","September 30, 2020","June 30, 2021","August 8, 2019",,"August 8, 2019","Centre de recherche sur les filarioses et autres maladies tropicales (CRFilMT), Yaoundé, Cameroon",,"https://ClinicalTrials.gov/show/NCT04049851"
71,"NCT03075891","Oracea Soolantra Association in Patients With Severe Rosacea","ANSWER","Completed","Has Results","Rosacea","Drug: Ivermectin 1% cream|Drug: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|Other: Oral placebo capsules","Percent Change From Baseline in Inflammatory Lesion Count","Galderma","All","18 Years and older   (Adult, Older Adult)","Phase 4","273","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.03.SPR.113322","July 5, 2017","February 8, 2018","February 8, 2018","March 9, 2017","November 29, 2019","November 29, 2019","Private Practice, Fort Smith, Arkansas, United States|Private practice, Sacramento, California, United States|Private practice, Boca Raton, Florida, United States|Private practice, Louisville, Kentucky, United States|Private practice, Louisville, Kentucky, United States|Private Practice, Metairie, Louisiana, United States|Private practice, Omaha, Nebraska, United States|Private practice, Las Vegas, Nevada, United States|Private practice, Pflugerville, Texas, United States|Private practice, Markham, Canada|Private practice, Montréal, Canada|Private practice, Peterborough, Canada|Private practice, Richmond Hill, Canada|Private practice, Waterloo, Canada|Private practice, Budapest, Hungary|University, Debrecen, Hungary|Hospital, Miskolc, Hungary|Private practice, Pécel, Hungary|University, Pécs, Hungary|University, Szeged, Hungary|Private practice, Szolnok, Hungary","""Study Protocol: Version for all countries except Germany"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03075891/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03075891/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03075891"
72,"NCT03576313","Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination","MASSIV","Active, not recruiting","No Results Available","Malaria","Drug: dihydroartemisinin-piperaquine (DP)|Drug: ivermectin (IVM)|Other: standard malaria control interventions only","prevalence of malaria infection|Vector's parous rate|malaria prevalence|incidence of clinical (laboratory confirmed) malaria cases|serological markers of recent malaria|serological markers of recent Anopheles exposure|mosquito density|mosquito mortality|sporozoite rates in field-caught mosquitoes","London School of Hygiene and Tropical Medicine|Institute of Tropical Medicine, Belgium|National Malaria Control Programme, The Gambia|Liverpool School of Tropical Medicine|Radboud University|University of Durham|Imperial College London","All","6 Months and older   (Child, Adult, Older Adult)","Phase 3","6400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","SCC 1593","August 11, 2018","February 16, 2020","December 2021","July 3, 2018",,"March 6, 2020","Basse Villages, Basse Santa Su, Gambia",,"https://ClinicalTrials.gov/show/NCT03576313"
73,"NCT01903057","Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis","AZIVAL2","Withdrawn","No Results Available","Trachoma|Lymphatic Filariasis","Drug: azithromycin|Drug: ivermectin|Drug: albendazole|Drug: placebo","The overall rate of adverse events and serious adverse events in each group|The types of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy.|The incidences of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy.|The timing of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy.|The duration of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy.|The intensities of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy.","Emory University","All","5 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","IRB00065751|ITI2012-001","February 2014","March 2014","July 2014","July 19, 2013",,"May 22, 2014","National Institute of Health, Ministry of Health, Maputo, Mozambique",,"https://ClinicalTrials.gov/show/NCT01903057"
74,"NCT04041453","Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients","HI4T","Not yet recruiting","No Results Available","Trichuris Infection|Helminthiasis","Drug: Ivermectin|Drug: Albendazole","Cure rate|Egg Reduction Rate|Beta tubulin resistance","Alejandro Krolewiecki|Brock University, Department of Health Sciences. ON, Canada|UNCPBA, CIVETAN. Tandil, Argentina|Universidad Autonoma de Honduras, Instituto de Investigaciones en Microbiología. Tegucigalpa, Honduras|Universidad Nacional de Salta","All","2 Years to 14 Years   (Child)","Phase 2","177","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","01-2019","August 15, 2019","November 30, 2019","April 30, 2020","August 1, 2019",,"August 5, 2019","IIET, Oran, Salta, Argentina",,"https://ClinicalTrials.gov/show/NCT04041453"
75,"NCT03177993","Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji","FIT","Completed","No Results Available","Lymphatic Filariases|Scabies|Impetigo|Soil Transmitted Helminths","Drug: 3 drug dose - IDA|Drug: 3 drug dose - IDA with second dose of ivermectin|Drug: 2 drug dose - DA","Frequency, type, and severity of adverse events reported by participants following treatment with triple drug therapy (IDA) and standard two drug therapy (DA) in LF infected and uninfected individuals in a community as measured by CTCAE v4.03|Clearance of microfilariae (mf) and filarial antigenemia following treatment with IDA or DA in LF infected individuals as measured by microfilaria count in 60ul thick blood smears and filarial test strip rapid diagnostic antigen test.|Prevalence of scabies in study population measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm|Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR at baseline and 12 months after treatment|Acceptability and feasibility of IDA and DA in communities at risk of LF, scabies and STH as assessed by survey and focus group discussions.|Prevalence of impetigo measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm","Washington University School of Medicine|The Task Force for Global Health|Murdoch Children's Research Institute","All","Child, Adult, Older Adult","Not Applicable","4773","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201607068-2","July 13, 2017","November 22, 2017","October 24, 2019","June 6, 2017",,"January 13, 2020","Ministry of Health and Medical Services, Suva, Fiji",,"https://ClinicalTrials.gov/show/NCT03177993"
76,"NCT03664063","PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )",,"Completed","No Results Available","Lymphatic Filariasis|Yaws|Trauma","Drug: Azithromycin|Drug: Albendazole|Drug: Ivermectin|Drug: Diethylcarbamazine","Drug levels of Azithromycin, Ivermectin, Diethylcarbamazine, Albendazole|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Lihir Medical Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ComboNTDs-PK","September 1, 2018","October 1, 2018","January 1, 2019","September 10, 2018",,"February 28, 2019","Lihir Medical Centre, Londolovit, New Ireland Province, Papua New Guinea",,"https://ClinicalTrials.gov/show/NCT03664063"
77,"NCT04056325","Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloidiasis Stercoralis","StrongMoxy","Enrolling by invitation","No Results Available","Strongyloides Stercoralis Infection","Drug: Moxidectin|Drug: Ivermectin|Drug: Placebo oral tablet","Cure rate against Strongyloidiasis stercoralis|Larvae-reduction rate (LRR) against Strongyloidiasis stercoralis|CRs and LRRs against concomitant soil-transmitted helminth infections|Number of participants reporting adverse events|Maximum concentration (Cmax) of moxidectin in adults|Time to reach Cmax (tmax) of moxidectin in adults|Area under the curve (AUC) of moxidectin in adults|Elimination half life (t1/2) of moxidectin in adults","Jennifer Keiser|National Institute of Public Health, Vientiane, Laos|National Centre for Parasitology, Entomology and Malaria Control, Cambodia|Swiss Tropical & Public Health Institute","All","18 Years to 60 Years   (Adult)","Phase 2","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","3","January 23, 2020","September 1, 2021","September 1, 2021","August 14, 2019",,"January 27, 2020","National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia|National Institute of Public Health, Vientiane, Lao People's Democratic Republic",,"https://ClinicalTrials.gov/show/NCT04056325"
78,"NCT00262418","Comparison of the Efficacy and Safety of Ivermectin to Permethrin",,"Completed","No Results Available","Scabies","Drug: Administration of ivermectin or permethrin","Clinical healing of the skin injuries|Decrease of itching|Amelioration of the life quality|Number and gravity of adverse events","University Ghent","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","2004/212","July 2004",,"May 2005","December 6, 2005",,"December 28, 2007","University Hospital Ghent, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT00262418"
79,"NCT04174469","Ivermectin Neurotoxicity and ABCB1 Gene Mutations",,"Completed","No Results Available","DNA Sequencing",,"Identified mutations Biological|Identified Biological diagnostic","University Hospital, Montpellier|Toulouse University Hospital|National Veterinary School of Toulouse (INTHERES, UMR 1436, INRA, ENVT)","All","10 Years to 45 Years   (Child, Adult)",,"3","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","RECHMPL19_0176","October 10, 2017","April 1, 2019","April 30, 2019","November 22, 2019",,"November 26, 2019","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04174469"
80,"NCT00604084","Veron Scabies Education and Eradication Program","VSEEP","Completed","No Results Available","Scabies","Drug: Ivermectin|Drug: Permethrin 5% lotion","Scabies incidence|Scabies-induced skin abscess incidence|Incidence of Lindane prescription and use|Incidence of Ivermectin prescription and use|Scabies disease, treatment, and prevention awareness","Edward Via Virginia College of Osteopathic Medicine","All","Child, Adult, Older Adult","Not Applicable","1057","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB#2007/006","May 2007","May 2008","May 2008","January 29, 2008",,"July 22, 2019","Barrio Nuevo, Veron, La Altagracia, Dominican Republic",,"https://ClinicalTrials.gov/show/NCT00604084"
81,"NCT02616250","MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.","MOSAIC","Completed","Has Results","Rosacea","Drug: Brimonidine 0.33% gel (Br)|Other: CD07805/47 (Br) placebo gel|Drug: Ivermectin 1% cream (IVM)|Other: CD5024 (IVM) placebo cream","Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA):","Galderma","All","18 Years and older   (Adult, Older Adult)","Phase 4","190","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RD.03.SPR.105069","December 2015","September 2016","September 2016","November 26, 2015","October 19, 2017","March 12, 2018","Fort Smith, Arkansas, United States|Rogers, Arkansas, United States|Sacramento, California, United States|Orlando, Florida, United States|Omaha, Nebraska, United States|New York, New York, United States|Pflugerville, Texas, United States|Surrey, British Columbia, Canada|Markham, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02616250"
82,"NCT00207753","Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections",,"Completed","No Results Available","Ascariasis|Trichuriasis|Hookworm Infection|Strongyloidiasis|Pediculosis","Drug: albendazole vs. combined albendazole/ivermectin treatment","efficacy against geohelminths (stool egg count)|height increase|weight increase|ectoparasite examination","Centers for Disease Control and Prevention|Universidad del Valle, Guatemala","All","5 Years to 12 Years   (Child)","Not Applicable","550","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CDC-NCID-4283","February 2005",,"March 2005","September 21, 2005",,"November 17, 2005","Various elementary schools, Poptun, Peten, Guatemala",,"https://ClinicalTrials.gov/show/NCT00207753"
83,"NCT03238131","IVM Alone vs ALB + IVM Against Onchocerciasis",,"Completed","No Results Available","Onchocerciasis","Drug: Ivermectin|Drug: Albendazole","The percent fertile female O.volvulus worms in nodules|Percent reduction in skin Mf/mg|Number of nodules with intact Mf|Soil Transmitted Helminth (STH) infections","University Hospitals Cleveland Medical Center|Washington University School of Medicine","All","18 Years to 60 Years   (Adult)","Phase 3","272","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11-11-36","April 2012","April 2015","October 2016","August 3, 2017",,"August 29, 2017","Committee on Human Research Publications and Ethics, Kumasi, Ashanti, Ghana",,"https://ClinicalTrials.gov/show/NCT03238131"
84,"NCT02032043","Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)",,"Completed","No Results Available","Lymphatic Filariasis|Onchocerciasis|Soil Transmitted Helminth (STH) Infections","Drug: Annual versus Semiannual Albendazole plus Ivermectin MDA","Microfilaria prevalence based on results of microscopic examination of blood smears and skin snips.|Prevalence of filarial antigenemia in blood and intensity of filarial and intestinal worm infections based on results of microscopy.","Washington University School of Medicine","All","5 Years and older   (Child, Adult, Older Adult)",,"14457","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","201306100","February 2014","December 4, 2017","December 4, 2017","January 9, 2014",,"May 4, 2018","Ivory Coast National Program Against Schistosomiasis, Geohelminths and Filariasis, Abidjan, Lagune-Cocody, Côte D'Ivoire",,"https://ClinicalTrials.gov/show/NCT02032043"
85,"NCT01905436","Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia","DOLF-LIBERIA","Enrolling by invitation","No Results Available","Lymphatic Filariasis|Onchocerciasis|Soil Transmitted Helminth (STH) Infections","Drug: Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration","Prevalence of W. bancrofti microfilaria (4 years)|Prevalence of W. bancrofti filarial antigenemia (4 years)|Prevalence of O. volvulus microfilaria (4 years)|Community egg load of soil transmitted helminth (STH) eggs (4 years)|Prevalence of W. bancrofti microfilaria (7 years)|Prevalence of W. bancrofti filarial antigenemia (7 years)|Prevalence of O. volvulus microfilaria (7 years)|Community egg load of soil transmitted helminth (STH) eggs (7 years)","Washington University School of Medicine","All","5 Years and older   (Child, Adult, Older Adult)",,"21862","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","201107185","March 2012","April 2017","July 2020","July 23, 2013",,"January 28, 2020","Liberian Institute of Biomedical Research, Charlesville, Margibi, Liberia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT01905436/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT01905436/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01905436"
86,"NCT01308268","Management of Soil-transmitted Helminthiasis and Strongyloidiasis",,"Unknown status","No Results Available","Helminthiasis|Strongyloides Stercoralis Infection","Drug: Ivermectin + Albendazole","Evaluation of local epidemiology of soil-transmitted helminthiases and impact of a mass drug treatment anti-helminthic strategy|Validate serology methods for diagnosis of S. stercoralis infection|Assess the tolerability and safety of the combination of ivermectin and albendazole","Universidad Nacional de Salta|Fundación Mundo Sano|Albert B. Sabin Vaccine Institute","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIET-05","December 2010","April 2012","April 2012","March 4, 2011",,"March 4, 2011","Instituto de Investigación en Enfermedades Tropicales, Universidad Nacional de Salta, Orán, Salta, Argentina",,"https://ClinicalTrials.gov/show/NCT01308268"
87,"NCT04410406","Moxidectin for LF, Cote d'Ivoire (DOLF)",,"Recruiting","No Results Available","Lymphatic Filariasis","Drug: IA (IVM+ ABZ)|Drug: MoxA (Mox + ABZ)|Drug: IDA (IVM + DEC + ABZ)|Drug: MoxDA (Mox + DEC + ABZ)","Clearance of microfilaremia (IA vs. MoxA)|Clearance of microfilaremia (IDA vs. MoxDA)|Clearance of microfilaremia|Reduction in Mf counts|Reduction in circulating filarial antigen (CFA) counts|Inactivation of adult worm nests|Frequency and severity of AEs|Plasma levels of drugs/metabolites post treatment","Washington University School of Medicine|Case Western Reserve University|Regional Hospital of Agboville, Southern Cote d'Ivoire","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202005076","July 1, 2020","September 1, 2022","September 1, 2023","June 1, 2020",,"June 1, 2020","Regional Hospital of Agboville, Southern Cote d'Ivoire, Agboville, Côte D'Ivoire",,"https://ClinicalTrials.gov/show/NCT04410406"
88,"NCT02078024","Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana",,"Completed","No Results Available","Onchocerciasis","Drug: IVM plus ALB|Drug: IVM","parasitologic efficacy|additional measures of parasitologic efficacy|compare the percentage living versus dead female worms|compare the number of nodules with intact microfilaria|assess different treatment regimens on Soil Transmitted Helminth infections|determine if IVM plus ALB enhances immunological reactions|determine if the host immune response facilitates killing or sterilizing adult worms and microfilariae","University Hospitals Cleveland Medical Center","All","18 Years to 60 Years   (Adult)","Phase 3","375","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","WU-10-205|CWRU-OCR-1","June 2014","June 2018","June 25, 2018","March 4, 2014",,"April 26, 2019","Onchocerciasis Chemotherapy Research Centre, (OCRC) Municipal Hospital, Hohoe, Ghana",,"https://ClinicalTrials.gov/show/NCT02078024"
89,"NCT03173742","Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)",,"Completed","No Results Available","Helminthiasis","Drug: T1, T2, T3|Drug: T1,T3,T2|Drug: T2,T1,T3|Drug: T2,T3,T1|Drug: T3,T1,T2|Drug: T3,T2,T1","Primary endpoint evaluated will be the PK parameters that define bioavailability in extent Ln [AUC0t]|Primary endpoint evaluated will be the PK parameters that define bioavailability in extent in rate: Ln [Cmax] for each treatment in healthy volunteers with high weight (Group 3), calculated by means of a non-compartmental analysis.|Relative bioavailability for each treatment and for groups 1 and 2 will be evaluated with the PK parameters that define bioavailability in extent Ln [AUC0t]|Relative bioavailability for each treatment and for groups 1 and 2 will be evaluated with the PK parameters that define bioavailability in extent in rate: Ln [Cmax]|AUC0t (for non-compartmental analysis)|AUC0∞ (for non-compartimental analysis)|%AUC extra (residual area) (for non-compartimental analysis)|tmax (for non-compartimental analysis)|tlag (for non-compartimental analysis)|Cl/F (for non-compartimental analysis)|V/F (for non-compartimental analysis)|t1/2 (for non-compartimental analysis)|Ke (for non-compartimental analysis)|MRT (for non-compartimental analysis)|Cmax (for non-compartimental analysis)|tlag (for compartimental analysis)|ka (for compartimental analysis)|Cl/F(for compartimental analysis)|V/F (for compartimental analysis)|vital signs|laboratory analysis|Incidence of adverse events.|ECG","Insud Pharma","All","18 Years to 45 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS842-101|2015-005690-20","March 2016","December 2016","January 2017","June 2, 2017",,"June 2, 2017",,,"https://ClinicalTrials.gov/show/NCT03173742"
90,"NCT03676140","Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )",,"Completed","No Results Available","Trachoma|Yaws|Lymphatic Filariases|Scabies|Strongyloidiasis","Drug: Albendazole on Day 1|Drug: Ivermectin on Day 1|Drug: Diethylcarbamazine on day 1|Drug: Azithromycin on Day 1|Drug: Azithromycin on Day 8","Self Reported Adverse Event","Lihir Medical Centre|London School of Hygiene and Tropical Medicine","All","Child, Adult, Older Adult","Phase 3","20000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ComboNTDs - CRT","October 1, 2018","December 15, 2018","January 1, 2019","September 18, 2018",,"February 28, 2019","Namatanai Hospital, Namatanai, Papua New Guinea",,"https://ClinicalTrials.gov/show/NCT03676140"
91,"NCT01586169","Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination","AZIVAL","Completed","No Results Available","Parasitic Diseases|Bacterial Diseases","Drug: triple co administration at once of the combination of Albendazole + ivermectin + azithromycin","Establish the incidence of adverse events associated with the mass triple drug administration|Establish the incidence of serious adverse events associated with the mass triple drug administration","Centre d'Appui à la lutte contre la Maladie|International Trachoma Initiative","All","5 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNAM/AZIVAL/01|0958/FMPOS","February 2010","February 2010","February 2010","April 26, 2012",,"April 26, 2012","Centre National D'Appui a la lutte contre la Maladie, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT01586169"
92,"NCT00300768","Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection",,"Completed","No Results Available","Onchocerciasis","Drug: 2 mg moxidectin|Drug: ivermectin 150 mcg/kg|Drug: 4 mg moxidectin|Drug: 8 mg moxidectin","Incidence of clinical adverse events and clinically significant laboratory test results|Skin mf counts at day 8 and months 1, 2, 3, 6, 12 and 18|Nodulectomy at 18 months|Pharmacokinetics (PKs) at days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12","Medicines Development for Global Health|World Health Organization","All","18 Years to 60 Years   (Adult)","Phase 2","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OCRC-33 - 980819(B)","September 2006","November 2009","November 2009","March 9, 2006",,"November 17, 2017","Onchocerciasis Chemotherapy Research Center, Hohoe, Volta Region, Ghana",,"https://ClinicalTrials.gov/show/NCT00300768"
93,"NCT02568098","Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects",,"Completed","No Results Available","Drug Combination|Pharmacokinetics|Healthy","Drug: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Drug: PQ and DHA-PQP and PQ|Drug: DHA-PQP","Number of Participants with Adverse Events|Area under the concentration-time curve AUC(0-∞)|Area under the concentration-time curve AUC(0-last)|Maximal concentration (Cmax)|Elimination clearance (CL/F)|Terminal elimination half-life (t1/2)|Apparent volume of distribution (Vd) for PQ, DHA-PQP, IVM, ABZ.|Pharmacogenetic polymorphisms in case of abnormal drug level|Pharmacokinetic differences of AUC(0-∞) for IVM between venous and capillary blood|Pharmacokinetic differences of AUC(0-last) between venous and capillary blood|Pharmacokinetic differences of Cmax between venous and capillary blood|Mosquito survivorship","University of Oxford|Mahidol University|Mahidol Oxford Tropical Medicine Research Unit","All","18 Years to 60 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FTM1501","October 2015","December 2016","December 2016","October 5, 2015",,"May 31, 2017","Faculty of Tropical Medicine, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02568098"
94,"NCT01050517","Safety and Efficacy of Drug Combinations Against Triple Infections",,"Completed","No Results Available","Parasitic Diseases","Drug: albendazole + ivermectin + praziquantel|Drug: albendazole + ivermectin + (1 week later) praziquantel","adverse reactions|Efficacy of treatment","DBL -Institute for Health Research and Development","All","5 Years to 18 Years   (Child, Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AO.UGA.TRIPLE|DBL-CHRD","October 2007","December 2007","December 2007","January 15, 2010",,"January 15, 2010","Vector Control Division, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01050517"
95,"NCT00339417","Effect of Albendazole Dose on Clearance of Filarial Worms",,"Completed","No Results Available","Lymphatic Filariasis","Drug: Albendazole|Drug: Ivermectin","Wb microfilarial levels|Adult worm burden as assessed by circulating antigen levels and visualization of worm nests by ultrasound","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","1000","NIH","Interventional","Primary Purpose: Treatment","999906107|06-I-N107","February 22, 2006","August 1, 2008","August 17, 2011","June 21, 2006",,"July 2, 2017","University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT00339417"
96,"NCT04382846","Novel Regimens in COVID-19 Treatment",,"Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Drug: Nitazoxanide|Drug: Ivermectin|Drug: Chloroquine|Drug: Azithromycin","Number of patients with virological cure","Tanta University","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","tanta covid treatment","May 8, 2020","December 1, 2030","December 1, 2030","May 11, 2020",,"May 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04382846"
97,"NCT02899936","Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis",,"Completed","No Results Available","Lymphatic Filariasis","Drug: 3 drug dose - IDA|Drug: 2 drug dose - DA","Number of participants with treatment-related adverse events as assessed by modified CTCAE v4.0 scale|Number of participants with clearance of microfilaremia (MF) as measured with microfilaremia night blood smear testing (finger prick - 60ul)|Number of participants Filarial Test Strip (FTS) and/or MF positive as tested with FTS and night blood smears with treatment-related adverse events as assessed by modified CTCAE v4.0 scale|Community acceptance will be measured using on a survey using likert scale questions based on perception of efficacy, intent to participate and relevance of the treatment.|Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR at baseline and 12 months after treatment","Washington University School of Medicine|Case Western Reserve University|Indian Council of Medical Research","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","23789","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201607068","July 2016","April 27, 2017","May 31, 2018","September 14, 2016",,"March 11, 2019","Ministere de la Sante Publique et de la Population, Port-au-Prince, Haiti|Vector Control Research Centre, Puducherry, India|Universitas Indonesia, Jakarta, Indonesia|Papua New Guinea Institute for Medical Research, Madang, Papua New Guinea","""Study Protocol: India specific protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02899936/Prot_000.pdf|""Study Protocol and Informed Consent Form: Papua New Guinea specific protocol + ICF"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02899936/Prot_ICF_001.pdf|""Study Protocol and Informed Consent Form: Haiti specific protocol + ICF"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02899936/Prot_ICF_002.pdf|""Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Indonesia specific protocol + ICF"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02899936/Prot_SAP_ICF_003.pdf","https://ClinicalTrials.gov/show/NCT02899936"
98,"NCT02974049","Lymphatic Filariasis (LF) in Ivory Coast",,"Completed","No Results Available","Lymphatic Filariasis","Drug: Albendazole|Drug: Ivermectin|Drug: Diethylcarbamazine","Total clearance of Microfilariae|Total clearance of MF at 24 months|Percent MF reduction|Reduction in W. bancrofti antigen level|Alere Filariasis Test Strip negative|reduction in viable worm nests|Diversity of parasites|type and level of parasite-specific host immune response","University Hospitals Cleveland Medical Center|Washington University School of Medicine","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","189","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","08-14-13","January 2015","September 2018","September 25, 2018","November 28, 2016",,"April 26, 2019",,,"https://ClinicalTrials.gov/show/NCT02974049"
99,"NCT00817713","Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?",,"Terminated","No Results Available","HIV Infections|Helminthiasis","Drug: Praziquantel, Ivermectin, Albendazole","Difference in HIV viral load between intervention and control arm|Difference in CD4 counts between intervention and control arm|Difference in time to meet criteria for the initiation of anti-retroviral treatment|occurrence of severe adverse events","Swiss Tropical & Public Health Institute|Ifakara Health Research and Development Centre|University Hospital Inselspital, Berne|Merck KGaA, Darmstadt, Germany","All","18 Years and older   (Adult, Older Adult)","Not Applicable","295","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","257/08","January 2009","September 2010","September 2010","January 6, 2009",,"February 16, 2011","Chronic Disease Clinic of St. Francis Designated District Hospital, Ifakara, Kilombero, Tanzania",,"https://ClinicalTrials.gov/show/NCT00817713"
100,"NCT03074435","Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire","REACT","Unknown status","No Results Available","Malaria","Device: Insecticidal paint|Device: Larvicide|Biological: Ivermectin|Behavioral: IEC","Malaria incidence|Entomological Inoculation Rate|Malaria prevalence","Institut de Recherche pour le Developpement|Institut de Recherche en Sciences de la Sante, Burkina Faso|Institut Pierre Richet","All","6 Months to 20 Years   (Child, Adult)","Phase 3","18000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","InstitutRD","April 2016","October 2017","April 2019","March 8, 2017",,"March 10, 2017",,,"https://ClinicalTrials.gov/show/NCT03074435"
101,"NCT04108897","Analysis of the Microbiome in Rosacea",,"Active, not recruiting","No Results Available","Rosacea","Drug: Doxycycline|Drug: Ivermectin Topical","Difference in skin and gut microbiome between rosacea and control|Change in skin and gut microbiome after 4-week of antimicrobial treatment in rosacea patients","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00210816","September 17, 2019","September 2022","September 2022","September 30, 2019",,"September 30, 2019","Cutaneous Translational Research Program, Department of Dermatology, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04108897"
102,"NCT04374019","Novel Agents for Treatment of High-risk COVID-19 Positive Patients",,"Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate","Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function","Susanne Arnold|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20-COVID-01-PMC","May 1, 2020","May 2021","May 2021","May 5, 2020",,"May 7, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04374019"
103,"NCT04188301","Safety and Efficacy of IDA for Onchocerciasis","DOLF IDA/Oncho","Enrolling by invitation","No Results Available","Onchocerciasis","Drug: IVM w/ ALB|Drug: Single dose of IDA|Drug: Three daily doses of IDA","Rates/types of severe adverse events (SAEs) across study arms|Percentage of worms killed/sterilized across study arms|Rates of SAEs by treatment group in those with intraocular mf just prior to treatment with IDA|Rates of ocular adverse events (any grade) by treatment group|Effectiveness of killing adult female worms|Effectiveness of clearing microfilariae from skin by skin snips|Effectiveness for preventing reappearance of microfilariae in the skin by skin snips","Washington University School of Medicine|Case Western Reserve University|University of Health and Allied Sciences","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","201","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201910085","December 6, 2019","January 2022","January 2022","December 5, 2019",,"May 22, 2020","University of Health and Allied Sciences, Hohoe, Ghana",,"https://ClinicalTrials.gov/show/NCT04188301"
104,"NCT03236168","Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands",,"Completed","Has Results","Scabies|Head Lice","Drug: Ivermectin|Drug: Permethrin 5%|Drug: Malathion Shampoo 0.5%","Number of Participants With Headlice","London School of Hygiene and Tropical Medicine","All","Child, Adult, Older Adult","Phase 3","118","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14257","August 1, 2017","December 31, 2017","February 28, 2018","August 1, 2017","June 14, 2019","June 14, 2019","Atoifi Adventist Hospital, Atoifi, Malaita, Solomon Islands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03236168/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03236168"
105,"NCT03598842","Tuberculosis - Learning the Impact of Nutrition","TB-LION","Suspended","No Results Available","Tuberculosis|Malnutrition|Helminth Infection","Dietary Supplement: Nutritional Supplementation Meal|Dietary Supplement: Multivitamin|Drug: Anti-parasitic medications","Immune response|Immune Response|Anthropometric measurement|Anthropometric measurements","Boston Medical Center|Rutgers, The State University of New Jersey|Jawaharlal Institute of Postgraduate Medical Education & Research","All","18 Years to 55 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-37473|6005415","July 12, 2019","December 2023","December 2023","July 26, 2018",,"April 7, 2020","Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT03598842"
106,"NCT00215280","Epidemiology and Control of Mansonella Perstans Infection in Uganda",,"Completed","No Results Available","Mansonelliasis|Pruritus|Lymphoedema|Abdominal Pains","Drug: ivermectin and albendazole","microfilariae periodicity patterns|epidemiology of M. perstans at community level|clinical spectre among infected|reduction in microfilaraemia|treatment effect on clinical manifestations","DBL -Institute for Health Research and Development|Ministry of Health, Uganda","All","5 Years and older   (Child, Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","MV917090205","November 2005",,"February 2006","September 22, 2005",,"April 20, 2007","Luwero, Luwero and Mukono, Luwero and Mukono Districts, Uganda",,"https://ClinicalTrials.gov/show/NCT00215280"
107,"NCT01050452","Safety and Efficacy of Drug Combinations Against Trichuris Trichiura",,"Completed","No Results Available","Parasitic Diseases","Drug: albendazole|Drug: mebendazole|Drug: ivermectin|Drug: albendazole + ivermectin|Drug: mebendazole + ivermectin","Record adverse reactions|Efficacy of treatment","DBL -Institute for Health Research and Development","All","5 Years to 15 Years   (Child)","Not Applicable","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AO.UGA.TRI|DBL-CHRD","October 2007","August 2009","August 2009","January 15, 2010",,"January 15, 2010","Vector Control Division, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01050452"
108,"NCT04345419","A Real-life Experience on Treatment of Patients With COVID 19",,"Not yet recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide|Drug: Other drugs","Number of patients with decreased viral load","Tanta University","All","Child, Adult, Older Adult","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","COVID 19 treatment","April 30, 2020","December 2029","December 2029","April 14, 2020",,"April 29, 2020","Tanta university hospital, Tanta, Egypt",,"https://ClinicalTrials.gov/show/NCT04345419"
109,"NCT02795117","Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea",,"Completed","No Results Available","Rosacea","Drug: Ivermectin|Drug: Ivermectin (reference)|Drug: Placebo","Mean percent change from baseline in the inflammatory (papules and pustules) lesion count|Subjects with clinical success on the Investigator Global Assessment (IGA)","Perrigo Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","485","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRG-NY-15-013","May 2016","February 2017","February 2017","June 9, 2016",,"February 22, 2018",,,"https://ClinicalTrials.gov/show/NCT02795117"
110,"NCT03352206","Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis",,"Recruiting","No Results Available","Lymphatic Filariases","Drug: 2 drug dose - DA|Drug: 3 drug dose - IDA","Number of participants with circulating filarial antigenemia (CFA) as measured by the Filaria Test Strip|Number of participants with IgG4 antifilarial antibodies in plasma|Number of participants with microfilaremia as measured with night blood smear testing|Community prevalence of microfilaremia as measured with night blood smear|Community prevalence of circulating filarial antigen as measured with filarial test strip|Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR","Washington University School of Medicine|Case Western Reserve University|Ministere de la Sante Publique et de la Population, Haiti|Indonesia University|Papua New Guinea Institute for Medical Research","All","5 Years and older   (Child, Adult, Older Adult)",,"22500","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201710040","January 1, 2016","December 2019","December 2019","November 24, 2017",,"September 30, 2019","Ministry of Health and Medical Services, Suva, Fiji|Ministere de la Sante Publique et de la Population, Port-au-Prince, Haiti|Vector Control Research Centre, Puducherry, India|Universitas Indonesia, Jakarta, Indonesia|Papua New Guinea Institute for Medical Research, Madang, Papua New Guinea",,"https://ClinicalTrials.gov/show/NCT03352206"
111,"NCT00340691","Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis",,"Completed","No Results Available","Mansonella Perstans Infection|Mp Microfilaremia","Drug: Doxycycline","Greater than or equal to 50 percent of Mp microfilaremia at 1 year in response to doxycycline treatment in study volunteers with Mp infection.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","1500","NIH","Interventional","Primary Purpose: Treatment","999905053|05-I-N053","December 6, 2004","October 4, 2007",,"June 21, 2006",,"July 2, 2017","National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00340691"
112,"NCT01287663","Effectiveness of Permethrin Impregnated Underwear in Preventing Louse Proliferation in Infected Homeless","ERPOUPER","Terminated","No Results Available","Body's Louses","Drug: Permethrin impregnated|Drug: no Permethrin impregnated","Show that underwear soaked with permethrine in 8 % allow to reduce in a long-lasting way (J90 and J365) of 50 % the index of infestation and prevalency of the louses in the group treated with regard to the group placebo.","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","125","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2010-A01406-33|2010 30","January 2011","May 2012","May 2012","February 1, 2011",,"August 29, 2014","Assistance Publique Hopitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT01287663"
113,"NCT03014167","Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)",,"Recruiting","No Results Available","Helminthiasis|Filariasis","Drug: Albendazole","STH transmission interruption","Natural History Museum, United Kingdom|Bill and Melinda Gates Foundation|University of Washington|Imperial College London|London School of Hygiene and Tropical Medicine|Institut de Recherche Clinique du Bénin (IRCB)|Institut de Recherche pour le Developpement|Christian Medical College, Vellore, India|Blantyre Institute for Community Ophthalmology (BICO)|Swiss Tropical & Public Health Institute","All","12 Months and older   (Child, Adult, Older Adult)","Phase 3","380000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DeWorm3 Project","October 4, 2017","December 2023","December 2023","January 9, 2017",,"August 21, 2019","Institut de Recherche pour le Développement, Comé, Benin|Christian Medical College, Vellore, India|London School of Hygiene and Tropical Medicine, Mangochi, Malawi",,"https://ClinicalTrials.gov/show/NCT03014167"
114,"NCT01730313","Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012",,"Unknown status","No Results Available","Nodding Syndrome","Drug: Pyridoxine|Drug: Sodium Valproate|Drug: Phenytoin|Drug: Placebo","Change in the frequency of observed head nodding and other seizure activity from baseline (which is the frequency at week 1)","Centers for Disease Control and Prevention|Ministry of Health, Uganda","All","5 Years to 17 Years   (Child)","Phase 2","80","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDC-CGH-6318","February 2013","September 2013","September 2013","November 21, 2012",,"November 21, 2012","Kitgum Nodding Syndrome Treatment Center, Kitgum General Hospital, Kitgum, Uganda",,"https://ClinicalTrials.gov/show/NCT01730313"
115,"NCT03131401","Prevalence of LF Infection in Districts Not Included in LF Control Activities",,"Completed","No Results Available","Lymphatic Filariases|Onchocerciasis","Diagnostic Test: Diagnosis of lymphatic filariasis|Diagnostic Test: Diagnosis of lymphatic Filariasis and onchocerciasis|Diagnostic Test: DEC Patch","Prevalence of lymphatic Filariasis|Measures of protection|Prevalence on Onchocerciasis|Vectors of lymphatic Filariasis|Wuchereria bancrofti infection in vectors|Performance of diagnostic tests","Noguchi Memorial Institute for Medical Research|Ghana Health Service, Neglected Tropical Diseases Program","All","5 Years and older   (Child, Adult, Older Adult)",,"3736","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","TDR B40376","January 21, 2018","August 30, 2018","August 30, 2018","April 27, 2017",,"October 11, 2018","Villages in Eastern and Volta Region, Eastern And Volta Regions, Ghana",,"https://ClinicalTrials.gov/show/NCT03131401"
116,"NCT00001245","Study of Patients With Strongyloides Stercoralis Infection",,"Completed","No Results Available","HIV Infection|Nematode Infection|Strongyloidiasis",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","8 Years to 80 Years   (Child, Adult, Older Adult)",,"650","NIH","Observational",,"890174|89-I-0174","August 1989","May 2009",,"November 4, 1999",,"August 25, 2009","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001245"
117,"NCT04124250","East New Britain Province Monitoring & Evaluation","ENBP M&E","Recruiting","No Results Available","Lymphatic Filariasis Elimination by Mass Drug Administration|Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis|Acceptability of Mass Drug Administration for Lymphatic Filariasis","Other: Observational","To determine the presence of W. bancrofti microfilariae|To determine the presence of W. bancrofti circulating antigen|To determine the presence and frequency anopheline mosquitos infected with lymphatic filariasis (Xenomonitoring)|To determine the knowledge and attitudes about lymphatic filariasis and acceptability of the mass drug program for lymphatic filariasis","University Hospitals Cleveland Medical Center|Case Western Reserve University|Washington University School of Medicine|Papua New Guinea Institute for Medical Research|Papua New Guinea ENB Provincial Health Authority|Papua New Guinea National Department of Health","All","5 Years to 80 Years   (Child, Adult, Older Adult)",,"10500","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","STUDY20191141","September 17, 2019","October 1, 2022","September 1, 2026","October 11, 2019",,"October 11, 2019","East New Britain Provincial Health Authority, Kokopo, East New Britain Province, Papua New Guinea",,"https://ClinicalTrials.gov/show/NCT04124250"
118,"NCT00001230","Host Response to Infection and Treatment in Filarial Diseases",,"Recruiting","No Results Available","Filariasis|Helminthiasis|Parasitic Infection|Mansonelliasis|Onchocerciasis",,"Define the determinants of the susceptibility to filarial infection, the development of filarial disease and the beneficial or adverse responseto therapy","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","3 Years to 100 Years   (Child, Adult, Older Adult)",,"500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","880083|88-I-0083","May 6, 1988",,,"November 4, 1999",,"February 28, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001230"
119,"NCT01080989","The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands",,"Completed","No Results Available","Flavivirus Infection|Alphavirus Infections|Malaria|Parasitic Disease|Leptospirosis|Hypertension|Metabolic Syndromes","Other: diagnosis, treatment and education","health screening for the community|Patients of confirmed malarial cases and those of cases suspicious of Flaviviral, Alpha-viral, Rickettsial,and Leptospiral infections.","Kaohsiung Medical University Chung-Ho Memorial Hospital","All","Child, Adult, Older Adult","Not Applicable","1477","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","KMUH-IRB-980096","March 2009","December 2011","December 2011","March 5, 2010",,"May 9, 2017","Kaoshing Medical University Chung-Ho Memorial Hospital, Kaoshiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01080989"
120,"NCT03653975","Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District","NSEC","Recruiting","No Results Available","Nodding Syndrome|Epilepsy|Onchocerciasis|Cognitive Impairment","Other: no intervention","Describing clinical features in children with Nodding Syndrome and other forms of epilepsy e.g. characteristics of the seizures, EEG abnormalities and reporting co-morbidities and impairments.|Describing EEG features in children with Nodding Syndrome and other forms|Measuring the rate of filarial infections in patients with NS, epilepsy and controls.|Characterization of O. volvulus in patients with Nodding Syndrome and epilepsy.|Characterization of the host immune response to O. volvulus.|Analyzing for genetic traits associated with epilepsy, NS, enhanced Ivermectin toxicity or specific immune responses.|Measuring the cognitive impairment in patients with NS and epilepsy.","Heidelberg University","All","3 Years to 99 Years   (Child, Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HD-DZIF-MUHAS","October 2014","May 2019","May 2019","August 31, 2018",,"August 31, 2018","Mahenge Epilepsy Clinic, Mahenge, Tanzania",,"https://ClinicalTrials.gov/show/NCT03653975"
121,"NCT03305978","Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.","npUBD","Completed","No Results Available","Lung Cancer|Smoking|Radiation Exposure","Device: Ultra low dose chest CT|Device: Low dose chest CT","Ultra low dose CT lung nodule detection sensibility|Ultra low dose CT diagnostic performances of lung nodule detection|Concordance of ≥4mm lung nodules characteristics between ultra low dose and standard low dose chest CT|Ultra low dose CT inter-observer reproducibility|Influence of subjects characteristics, nodule location, and nodule size on detection between ultra low dose and standard low dose chest CT|Concordance of emphysema characteristics between ultra low dose and standard low dose chest CT|Concordance of coronary calcification detection and quantification between ultra low dose and standard low dose chest CT|Concordance of bronchial abnormalities evaluation between ultra low dose and standard low dose chest CT","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","38RC17.132","September 26, 2017","July 10, 2019","July 10, 2019","October 10, 2017",,"August 21, 2019","University Hospital Grenoble, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT03305978"
122,"NCT02875756","Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis",,"Completed","No Results Available","Sarcoidosis","Procedure: 10 revolutions|Procedure: 20 revolutions","Diagnostic yield of EBUS-TBNA as indicated by the presence of granuloma|Adequacy of samples as indicated by the presence of lymphocytes","Postgraduate Institute of Medical Education and Research","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","NK/2232/study/1116","August 2016","December 2017","December 2017","August 23, 2016",,"August 24, 2018","Post Graduate Institute of Medical Education and Research, Chandigarh, UT, India",,"https://ClinicalTrials.gov/show/NCT02875756"
123,"NCT01869205","The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients",,"Completed","No Results Available","Pulmonary Emphysema","Device: Endobronchial valve","Quantitative change of lung volume on computed tomography|Pulmonary function test|Exercise capacity|Healthcare quality of life","Asan Medical Center","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 3","43","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSCR2013-0368|A102065","March 2013","April 2014","April 2017","June 5, 2013",,"June 27, 2017","Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01869205"
124,"NCT02366884","Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis (Atavistic Chemotherapy).",,"Recruiting","No Results Available","Neoplasms","Drug: Anti-Bacterial Agents|Drug: Anti-Fungal Agents|Drug: Anti-Protozoal Agents","Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response|Clinical safety as measured by the incidence of adverse events in each intervention group","Dr. Frank Arguello Cancer Clinic|Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com","All","1 Year to 75 Years   (Child, Adult, Older Adult)","Phase 2","250","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ACI/2015","July 2011","December 31, 2022","December 31, 2023","February 19, 2015",,"August 9, 2019","Dr. Frank Arguello Cancer Clinic, San Jose del Cabo, Baja California Sur, Mexico|Instituto de Ciencia y Medicina Genomica, Torreon, Coahuila, Mexico",,"https://ClinicalTrials.gov/show/NCT02366884"
125,"NCT00342576","Host Response to Infection and Treatment in Lymphatic Filarial Disease in India",,"Completed","No Results Available","Lymphatic Filarial Disease",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)",,"1500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","9999890048|OH89-I-0048","April 23, 1994",,"July 15, 2019","June 21, 2006",,"July 18, 2019","Tuberculosis Research Centre, Chennai, India",,"https://ClinicalTrials.gov/show/NCT00342576"
